Julia E. Wiedmeier
YOU?
Author Swipe
View article: Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance Open
View article: Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples
Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples Open
Background: Minimal residual disease (MRD) is a critical prognostic and therapeutic response marker in multiple myeloma (MM). Two main technologies are used for MRD assessment in bone marrow: next-generation flow cytometry (NGF) and next-g…
View article: Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies
Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies Open
Background The advent of T-cell redirecting bispecific antibodies (BsAb) therapies has led to deeper and durable responses in patients with RRMM. We sought to identify adverse prognostic factors for patients treated with BsAbs. We also exp…
View article: A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer
A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer Open
SUMMARY Background In this Phase II randomized clinical trial, we evaluated a medically supervised ketogenic diet (MSKD) compared to a usual diet (non-MSKD) when combined with the triplet chemotherapy regimen of gemcitabine, nab-paclitaxel…
View article: Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes Open
View article: Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention Open
Investigating venetoclax (VTX) resistance in multiple myeloma (MM) is crucial for the development of novel therapeutic strategies to tackle resistance. We conducted a multi-omic characterization of established VTX-resistant isogenic human …
View article: Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma
Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma Open
View article: Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations
Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations Open
Chronic lymphocytic leukemia (CLL) is characterized by multiple copy number alterations (CNAs) and somatic mutations that are central to disease prognosis, risk stratification, and mechanisms of therapy resistance. Fluorescence in situ hyb…
View article: Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients Open
View article: Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Open
View article: Differential prognosis of single and multiple <i>TP53</i> abnormalities in high-count MBL and untreated CLL
Differential prognosis of single and multiple <i>TP53</i> abnormalities in high-count MBL and untreated CLL Open
TP53 aberrations, including mutations and deletion of 17p13, are important adverse prognostic markers in chronic lymphocytic leukemia (CLL) but are less studied in high count monoclonal B-cell lymphocytosis (HCMBL), an asymptomatic pre-mal…
View article: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients Open
Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated with improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in comb…
View article: Bone marrow oxalosis with pancytopenia in a patient with short bowel syndrome: Report of a case and review of the literature
Bone marrow oxalosis with pancytopenia in a patient with short bowel syndrome: Report of a case and review of the literature Open
Systemic oxalosis is a condition in which calcium oxalate crystals deposit into various bodily tissues. Although this may occur as the result of a rare primary syndrome in which an error of glyoxylate metabolism causes an overproduction of…
View article: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients Open
Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is associated with improved survival outcomes. The role of highly sensitive next generation sequencing (NGS) MRD in comb…
View article: The Impact of COVID-19 on Physician–Scientist Trainees and Faculty in the United States: A National Survey
The Impact of COVID-19 on Physician–Scientist Trainees and Faculty in the United States: A National Survey Open
Purpose Physician–scientists have long been considered an endangered species, and their extended training pathway is vulnerable to disruptions. This study investigated the effects of COVID-19-related challenges on the personal lives, caree…
View article: Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup Open
Multiple myeloma is a disorder of the monoclonal plasma cells and is the second most common hematologic malignancy. Despite improvements in survival with newer treatment regimens, multiple myeloma remains an incurable disease and most pati…
View article: Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Open
View article: Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma Open
Background :COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Among patients with …
View article: Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies
Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies Open
PURPOSE: The benefit of routine pre-emptive screening for severe acute respiratory syndrome coronavirus 2 infections in patients with cancer before cancer-directed therapies is unclear. Herein, we characterize the outcomes of a cohort of p…
View article: Mortality and Glycemic Control Among Patients with Acute and Chronic Myeloid Leukemia and Diabetes: A Case–Control Study
Mortality and Glycemic Control Among Patients with Acute and Chronic Myeloid Leukemia and Diabetes: A Case–Control Study Open
No associations were found between leukemia, diabetes, survival and glycemic control.
View article: Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women
Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women Open
View article: Intrauterine growth restriction perturbs nucleosome depletion at a growth hormone-responsive element in the mouse IGF-1 gene
Intrauterine growth restriction perturbs nucleosome depletion at a growth hormone-responsive element in the mouse IGF-1 gene Open
Intrauterine growth restriction (IUGR) is a common human pregnancy complication. IUGR offspring carry significant postnatal risk for early-onset metabolic syndrome, which is associated with persistent reduction in IGF-1 protein expression.…